Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies

M. Hayashi,T. Kikuchi,T. Takada

DOI: https://doi.org/10.1007/s10067-016-3443-2

Clinical Rheumatology

Abstract:

What problem does this paper attempt to address?

Endovascular Therapy in Acute Ischemic Stroke: Time is Brain

An-Li WANG,Zhi-Cai CHEN,Fei-Na SHI,Min LOU

DOI: https://doi.org/10.3969/j.issn.1673-5765.2018.02.012

2018-01-01

Abstract:Endovascular therapy brings a breakthrough progress in treatment of ischemic patients with acute large artery occlusion. Recent years studies have shown that endovascular therapy is more highly time-dependent than intravenous thrombolysis in terms of clinical outcome. To reduce reperfusion time delay is important for the management and development of endovascular therapy. Optimization of emergency rescue work flow, utilization of rapid and effective imaging evaluation system and development of fast recanalization method of thrombectomy will be helpful in clinical promotion and application of endovascular therapy in treatment of acute ischemic stroke.
tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?

Jong S. Kim

DOI: https://doi.org/10.5853/jos.2019.00584

2019-05-31

Journal of Stroke

Abstract:Tissue plasminogen activator (tPA) is the only therapeutic agent approved to treat patients with acute ischemic stroke. The clinical benefits of tPA manifest when the agent is administered within 4.5 hours of stroke onset. However, tPA administration, especially delayed administration, is associated with increased intracranial hemorrhage (ICH), hemorrhagic transformation (HT), and mortality. In the ischemic brain, vascular remodeling factors are upregulated and microvascular structures are destabilized. These factors disrupt the blood brain barrier (BBB). Delayed recanalization of the vessels in the presence of relatively matured infarction appears to damage the BBB, resulting in HT or ICH, also known as reperfusion injury. Moreover, tPA itself activates matrix metalloproteases, further aggravating BBB disruption. Therefore, attenuation of edema, HT, or ICH after tPA treatment is an important therapeutic strategy that may enable clinicians to extend therapeutic time and increase the probability of excellent outcomes. Recently, numerous agents with various mechanisms have been developed to interfere with various steps of ischemia/ reperfusion injuries or BBB destabilization. These agents successfully reduce infarct volume and decrease the incidence of ICH and HT after delayed tPA treatment in various animal stroke models. However, only some have entered into clinical trials; the results have been intriguing yet unsatisfactory. In this narrative review, I describe such drugs and discuss the problems and future directions. These

peripheral vascular disease,clinical neurology
Silver Jubilee of Stroke Thrombolysis With Alteplase: Evolution of the Therapeutic Window

Yuanmei Pan,Guowen Shi

DOI: https://doi.org/10.3389/fneur.2021.593887

IF: 3.4

2021-03-01

Frontiers in Neurology

Abstract:In 1995, the results of a landmark clinical trial by National Institute of Neurological Disorders and Stroke (NINDS) made a paradigm shift in managing acute cerebral ischemic stroke (AIS) patients at critical care centers. The study demonstrated the efficacy of tissue-type plasminogen activator (tPA), alteplase in improving neurological and functional outcome in AIS patients when administered within 3 h of stroke onset. After about 12 years of efforts and the results of the ECASS-III trial, it was possible to expand the therapeutic window to 4.5 h, which still represents a major logistic issue, depriving many AIS patients from the benefits of tPA therapy. Constant efforts in this regards are directed toward either speeding up the patient recruitment for tPA therapy or expanding the current tPA window. Efficient protocols to reduce the door-to-needle time and advanced technologies like telestroke services and mobile stroke units are being deployed for early management of AIS patients. Studies have demonstrated benefit of thrombolysis guided by perfusion imaging in AIS patients at up to 9 h of stroke onset, signifying “tissue window.” Several promising pharmacological and non-pharmacological approaches are being explored to mitigate the adverse effects of delayed tPA therapy, thus hoping to further expand the current tPA therapeutic window without compromising safety. With accumulation of scientific data, stroke organizations across the world are amending/updating the clinical recommendations of tPA, the only US-FDA approved drug for managing AIS patients. Alteplase has been a part of our neurocritical care and we intend to celebrate its silver jubilee by dedicating this review article discussing its journey so far and possible future evolution.

neurosciences,clinical neurology
Drinking in a patchy environment: the effect of the price of water.

G. Collier,Deanne F. Johnson,Gabrielle Borin,C. Mathis

DOI: https://doi.org/10.1901/JEAB.1994.62-169

1994-09-01

Journal of the Experimental Analysis of Behavior

Abstract:Rats in a laboratory foraging paradigm searched for sequential opportunities to drink in two water patches that differed in the bar-press price of each "sip" (20 licks) of water within a bout of drinking (Experiment 1) or the price and size (10, 20, or 40 licks) of each sip (Experiment 2). Total daily water intake was not affected by these variables. The rats responded faster at the patch where water was more costly. However, they accepted fewer opportunities to drink, and thus had fewer drinking bouts, and drinking bouts were smaller at the more costly patch than at the other patch. This resulted in the rats consuming a smaller proportion of their daily water from the more costly patch. The size of the differences in bout frequency and size between the patches appears to be based on the relative cost of water at the patches. The profitability of each patch was calculated in terms of the return (in milliliters) on either effort (bar presses) or time spent there. Although both measures were correlated with the relative total intake, bout size, and acceptance of opportunities at each patch, the time-based profitability was the better predictor of these intake measures. The rats did not minimize bar-press output; however, their choice between the patches and their bout sizes within patches varied in a way that reduced costs compared to what would have been expended drinking randomly. These data accord well with similar findings for choices among patches of food, suggesting that foraging for water and food occurs on the basis of comparable benefit-cost functions: In each case, the amount consumed is related to the time spent consuming.
Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders

William M Armstead,Kumkum Ganguly,J W Kiessling,John Riley,Xiao-Han Chen,Douglas H Smith,Sherman C Stein,Abd A R Higazi,Douglas B Cines,Khalil Bdeir,Sergei Zaitsev,Vladimir R Muzykantov

DOI: https://doi.org/10.1111/j.1471-4159.2010.06613.x

Abstract:Stroke is a leading cause of morbidity and mortality. While tissue-type plasminogen activator (tPA) remains the only FDA-approved treatment for ischemic stroke, clinical use of tPA has been constrained to roughly 3% of eligible patients because of the danger of intracranial hemorrhage and a narrow 3 h time window for safe administration. Basic science studies indicate that tPA enhances excitotoxic neuronal cell death. In this review, the beneficial and deleterious effects of tPA in ischemic brain are discussed along with emphasis on development of new approaches toward treatment of patients with acute ischemic stroke. In particular, roles of tPA-induced signaling and a novel delivery system for tPA administration based on tPA coupling to carrier red blood cells will be considered as therapeutic modalities for increasing tPA benefit/risk ratio. The concept of the neurovascular unit will be discussed in the context of dynamic relationships between tPA-induced changes in cerebral hemodynamics and histopathologic outcome of CNS ischemia. Additionally, the role of age will be considered since thrombolytic therapy is being increasingly used in the pediatric population, but there are few basic science studies of CNS injury in pediatric animals.
Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.

Faha,J. Saver,Del Zoppo,Adams Hp,Jauch Ec,Harold P. Adams,Gj,G. del Zoppo,E. Jauch,Saver Jl

DOI: https://doi.org/10.1161/STROKEAHA.109.192535

IF: 10.17

2009-08-01

Stroke

Abstract:Current guidelines for the management of patients with acute ischemic stroke published by the American Heart Association Stroke Council include specific recommendations for the administration of intravenous recombinant tissue plasminogen activator (rtPA).1 Despite its effectiveness in improving neurological outcomes, the majority of patients with ischemic stroke are not treated with rtPA, largely because they arrive after the currently approved 3-hour time limit for administration of the medication. One of the potential approaches to increase treatment opportunities has been the designation of a longer time window for treatment.2–4 A recent prospective study, the European Cooperative Acute Stroke Study (ECASS)-3, has provided new data on rtPA (alteplase) treatment in the 3-to-4.5–hour window.5 The circumstances surrounding this study are important. In 2002, the European Medicines Evaluation Agency granted license for the use of rtPA for the treatment of ischemic stroke patients within 3 hours of symptom onset on condition of (1) the completion of a prospective registry of patient treatment experience with rtPA given within the 3-hour window from symptom onset (Safe Implementation of Thrombolysis in Stroke–Monitoring Study, or SITS-MOST)6 and (2) the completion of a prospective, randomized, placebo-controlled trial of rtPA administered between 3 and 4.5 hours after stroke onset, ECASS-3.5 SITS-MOST, which used a specified protocol, reported that the frequency of symptomatic intracerebral hemorrhage (per the SITS-MOST definition) at 24 hours after rtPA was 1.7% (95% confidence interval [CI] 1.4% to 2.0%; Figure 3 in Wahlgren et al6). The frequency of symptomatic intracerebral hemorrhage per the Cochrane/National Institute of Neurological Disorders and Stroke (NINDS) definition at 24 hours after rtPA was 7.3% (95% CI 6.7% to 7.9%). By comparison, this frequency was slightly less than 8.6% in data taken from a pool of randomized, controlled trials (Figure 2 in Wahlgren et al6). For efficacy, …

Medicine
Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries

Georgios Tsivgoulis,Odysseas Kargiotis,Andrei V Alexandrov

DOI: https://doi.org/10.1080/14737175.2017.1347039

Abstract:Intravenous tissue-plasminogen activator (tPA) remains the only approved systemic reperfusion therapy suitable for most patients presenting timely with acute ischemic stroke. Accumulating real-word experience for over 20 years regarding tPA safety and effectiveness led to re-appraisal of original contraindications for intravenous thrombolysis (IVT). Areas covered: This narrative review focuses on fast yet appropriate selection of patients for safe administration of tPA per recently expanded indications. Novel strategies for rapid patient assessment will be discussed. The potential for mobile stroke units (MSU) that shorten onset-to-needle time and increase tPA treatment rates is addressed. The use of IVT in the era of non-vitamin K antagonist oral anticoagulants (NOACs) is highlighted. The continuing role of IVT in large vessel occlusion (LVO) patients eligible for mechanical thrombectomy (MT) is discussed with regards to 'drip and ship' vs. 'mothership' treatment paradigms. Promising studies of penumbral imaging to extend IVT beyond the 4.5-hour window and in wake-up strokes are summarized. Expert commentary: This review provides an update on the role of IVT in specific conditions originally considered tPA contraindications. Novel practice challenges including NOAC's, MSU proliferation and bridging therapy (IVT&MT) for LVO patients, and the potential extension of IVT time-window using penumbral imaging are emerging as safe and potentially effective IVT applications.
Thrombolysis in Neuromedicine

Guntram W. Ickenstein,Stefan Isenmann,Jens Fiehler,Georg Gahn,Martin Schumacher,Joachim Klisch

DOI: https://doi.org/10.1007/s00062-008-8010-z

2008-06-01

Clinical Neuroradiology

Abstract:Background:The treatment of patients with cerebral infarction due to vascular stenosis/occlusion includes a range of therapeutic options such as intravenous recombinant tissue plasminogen activator (rtPA) application, thrombocyte aggregation inhibition, anticoagulation, intraarterial thrombolytic medication as well as carotid endarterectomy and endovascular procedures (angioplasty or stenting of extra- and intracranial vessels). Both the drug therapies and endovascular techniques are expected to expand significantly over the next few years. The challenge consists in achieving optimal patient selection for specific therapeutic options.Objective:This position paper is a review and expert consensus document in neuromedicine, concerning the bridging concept in neurovascular diseases. It is the authors' approach to propose guidelines designed to ensure that patients with acute stroke who may be candidates for rapid revascularization have a chance to receive this type of treatment. In this ongoing multidisciplinary discussion all organizational, technical and personnel resources provided by stroke centers and cooperating hospitals should be harmonized and optimized. To ensure that no valuable time is lost and that the available time is used optimally, it may make sense to start systemic application of rtPA for thrombolysis following a diagnosis of nonhemorrhagic brain infarct and confirmation of suitability by means of teleneuromedical systems (TNS) until interventional therapy options or intraarterial local treatment can be initiated. This so-called bridging technique can further increase the success rate of treatment compared to exclusive intraarterial procedures.Outlook and Recommendations:Endovascular therapeutic options are still considered difficult, expensive, and risky, and should be reserved for specialized centers with experienced staff. Therefore, the selection process must be extensive, thorough and precise and patients must be allocated to centers without delay. Through the diffusion of certain techniques, in particular CT- or MRI-guided techniques (CTA, CTP, MRA, DWI, PWI), specific endovascular therapy protocols can be customized to select certain subtypes of stroke. Optimal pathways for specific infarct subtypes, where combined therapy strategies (bridging concepts) are perhaps most attractive, but fairly difficult to establish, should be developed in the near future.

radiology, nuclear medicine & medical imaging,clinical neurology
What is the Role for Intra-Arterial Therapy in Acute Stroke Intervention?

Cumara B. O’Carroll,Mark N. Rubin,Brian W. Chong

DOI: https://doi.org/10.1177/1941874415587681

2015-06-04

The Neurohospitalist

Abstract:Intravenous recombinant tissue plasminogen activator continues to be first-line therapy for patients with acute ischemic stroke presenting within the appropriate time window, but one potential limitation is the low rate of recanalization in the setting of large artery occlusions. Intra-arterial (IA) treatment is effective for emergency revascularization of proximal intracranial arterial occlusions, but proof of benefit has been lacking until recently. Our goal is to outline the history of endovascular therapy and review both IA thrombolysis and mechanical interventions. In addition, we will discuss the impact of important trials such as the Third Interventional Management of Stroke (IMS3) trial, and the more recent trials Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE), Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial (EXTEND-IA), and Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment (SWIFT PRIME) on acute stroke management and the implications for the practicing neurohospitalist.
Intra-arterial neuroprotective therapy as an adjunct to endovascular intervention in acute ischemic stroke: A review of the literature and future directions

Thomas W Link,Alejandro Santillan,Athos Patsalides

DOI: https://doi.org/10.1177/1591019920925677

Abstract:Mechanical thrombectomy for acute ischemic stroke due to large vessel occlusion has been shown to significantly improve outcomes. However, despite efficient rates of recanalization (60-90%), the rates of functional independence remain suboptimal (14-58%), most likely due to pathways of cell death in the brain that have already committed despite successful reperfusion. Pharmacologic neuroprotection provides a potential means of preventing this inevitable damage through targeting excitotoxicity, reactive oxygen species, cellular apoptosis, and inflammation. Numerous clinical trials using various neuroprotective agents have failed, but the majority of these trials did not include endovascular reperfusion, and thus the drugs were not reaching the therapeutic target. Intra-arterial delivery of neuroprotective agents via the guide catheter already in place for mechanical thrombectomy could provide a way to deliver high doses directly to the affected territory while limiting systemic exposure. Agents that have shown promise via the intra-arterial route in preclinical as well as some clinical models include magnesium sulfate, verapamil, cold saline, stem cells, and various combined approaches. Targeted hypothermia, achieved with intra-carotid infusion of cold saline, may provide an effective means of achieving hypothermia of the ischemic tissue while avoiding the systemic effects that have limited its use previously. Combination therapy of targeted hypothermia and a cocktail of drugs that provide anti-excitotoxic, anti-oxidant, anti-apopototic, and anti-inflammatory effects may provide an ideal approach that deserves further study in clinical trials.
Current and future perspectives on the treatment of cerebral ischemia

Brandon R. Christophe,Shyle H. Mehta,Andrew L. A. Garton,Jonathan Sisti,E Sander Connolly

DOI: https://doi.org/10.1080/14656566.2017.1309022

2017-04-10

Expert Opinion on Pharmacotherapy

Abstract:INTRODUCTION: After heart disease and combined forms of cancer, stroke is the leading cause of death in the United States. Currently, tissue-plasminogen activator (tPA) thrombolysis is the only thrombolytic therapy that has been shown to improve patient outcome. Presently, the only antithrombotic drug treatment that has proven effective at improving acute ischemic stroke patient outcome is aspirin administration. Despite these studies, no clinical trials have yet demonstrated a reliably effective pharmacological treatment. Areas covered: We conducted a search of recent drug studies for ischemic stroke on clinicaltrials.gov in addition to a literature search for acute ischemic stroke therapy using PubMed. This review details our findings of recent advancements in the pharmacological treatment of acute ischemic stroke. Expert commentary: We concluded that recent attempts to establish new pharmacological treatment protocols for acute ischemic stroke have had limited success, but many Phase III and Phase IV clinical trials demonstrate promise. Moreover, several studies have demonstrated the efficacy of dual-antiplatelet therapies at reducing risk of secondary stroke. Studies for novel therapeutic targets for neuroprotection have been largely unsuccessful. Some trials had positive results; however, there is much room for improvement and other studies show promise in their preliminary stages.

pharmacology & pharmacy
Emerging agents for the treatment and prevention of stroke: progress in clinical trials

Apostolos Safouris,Georgios Magoufis,Georgios Tsivgoulis

DOI: https://doi.org/10.1080/13543784.2021.1985463

Abstract:Introduction: Recent years have witnessed unprecedented progress in stroke care, but unmet needs persist regarding the efficacy of acute treatment and secondary prevention. Novel approaches are being tested to enhance the efficacy of thrombolysis or provide neuroprotection in non-thrombolized patients. Areas covered: The current review highlights pharmaceutical agents under evaluation in clinical trials concerning the acute, subacute, and chronic phase post-stroke. We examine the evidence in favor of tenecteplase as an alternative thrombolytic drug to alteplase, nerinetide as a promising neuroprotective agent, and glibenclamide for reducing edema in malignant hemispheric infarction. We discuss the use of ticagrelor and the promising novel category of factor XI inhibitors in the subacute phase after stroke. We offer our insights on combined rivaroxaban and antiplatelet therapy, PCSK-9 inhibitors, and other non-statin hypolipidemic agents, as well as novel antidiabetic agents that have been shown to reduce cardiovascular events in the long-term. Expert opinion: Current approaches in stroke treatment and stroke prevention have already transformed stroke care from a linear one-for-all treatment paradigm to a more individualized approach that targets specific patient subgroups with novel pharmaceutical agents. This tendency enriches the therapeutic armamentarium with novel agents developed for specific stroke subgroups. Abbreviations: IVT: intravenous thrombolysis; RCTs: randomized-controlled clinical trials; TNK: Tenecteplase; COVID-19: Coronavirus 2019 Disease; EXTEND-IA TNK: The Tenecteplase versus Alteplase Before Endovascular Therapy for Ischemic Stroke trial; AIS: acute ischemic stroke; NNT: number needed to treat; MT: mechanical thrombectomy; sICH: symptomatic intracranial hemorrhage; mRS: modified Rankin Scale; AHA/ASA: American Heart Association/American Stroke Association; ESO: European Stroke Organization; NA-1: Nerinetide; ENACT: Evaluating Neuroprotection in Aneurysm Coiling Therapy; CTA: CT angiography; TIA: transient ischemic attack; CHANCE: Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events; LOF: loss-of-function; PRINCE: Platelet Reactivity in Acute Nondisabling Cerebrovascular Events; THALES: Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA [acetylsalicylic acid] for Prevention of Stroke and Death; CHANCE-2: Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II; FXI: Factor XI; PACIFIC-STROKE: Program of Anticoagulation via Inhibition of FXIa by the Oral Compound BAY 2433334-NonCardioembolic Stroke study; COMPASS: Cardiovascular Outcomes for People Using Anticoagulation Strategies; CANTOS-ICAD: Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease; SAMMPRIS: Stenting and Aggressive Medical Therapy for Preventing Recurrent Stroke in Intracranial Stenosis; WASID: Warfarin-Aspirin Symptomatic Intracranial Disease; SPARCL: Stroke Prevention by Aggressive Reduction in Cholesterol Levels; LDL-C: low-density lipoprotein cholesterol; TST: Treat Stroke to Target; IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trial; PCSK9: proprotein convertase subtilisin-kexin type 9; FOURIER: Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; CLEAR: Cholesterol Lowering via Bempedoic acid, an ACL-inhibiting Regimen; REDUCE-IT: Reduction of Cardiovascular Events With EPA Intervention Trial; STRENGTH: Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia; ACCORD: Action to Control Cardiovascular Risk in Diabetes; ADVANCE: Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation; VADT: Veterans Affairs Diabetes Trial; GLP-1R: Glucagon-like peptide-1 receptor; SGLT2: sodium-glucose cotransporter 2; CONVINCE: COlchicine for preventioN of Vascular Inflammation in Non-CardioEmbolic stroke; PROBE: Prospective Randomized Open-label Blinded Endpoint assessment.
A pilot protocol and review of triple neuroprotection with targeted hypothermia, controlled induced hypertension, and barbiturate infusion during emergency carotid endarterectomy for acute stroke after failed tPA or beyond 24-hour window of opportunity

Sherif Sultan,Yogesh Acharya,Nora Barrett,Niamh Hynes

DOI: https://doi.org/10.21037/atm-2020-cass-14

Abstract:An alternative to tissue plasminogen activator (tPA) failure has been a daunting challenge in ischemic stroke management. As tPA is time-dependent, delays can occur in definitive treatment while passively waiting to observe a clinical response to intravenous thrombolysis. Until today, uncertainty exists in the management strategy of wake-up stroke patients or those presenting beyond the therapeutic tPA window. Clinical dilemmas in these situations can prolong the transitional period of inertia, resulting in an adverse neurological outcome. We propose and review an innovative approach called triple neuro-protection (TNP), which encompasses three technical domains-targeted hypothermia, systemic induced hypertension, and barbiturates infusion, to protect the brain during carotid endarterectomy after failed tPA and/or beyond the 24-hour therapeutic mechanical thrombectomy window. This proposal assimilates discussion on the clinical evidence of the individual domains of TNP with our own clinical experience with TNP. Our first TNP was successfully employed in a 55-year-old man in 2015 while performing emergency carotid endarterectomy after he was referred to us 72 hours post tPA failure. The patient had a successful clinical outcome despite being in therapeutic inertia with 90-99% ipsilateral carotid stenosis and contralateral occlusion on presentation. In the last five years, we have safely used TNP in 25 selected cases with favourable clinical outcomes.
Hyperacute ischemic stroke care—Current treatment and future directions

Bruce CV Campbell

DOI: https://doi.org/10.1177/17474930241267353

2024-08-05

International Journal of Stroke

Abstract:International Journal of Stroke, Volume 19, Issue 7, Page 718-726, August 2024. A decade on from the first positive thrombectomy trials, hyperacute therapies for ischemic stroke continue to rapidly advance. Effective treatments remain limited to reperfusion, although several cytoprotective approaches continue to be investigated. Intravenous fibrinolytics are now demonstrated to be beneficial up to 24 h in patients selected using perfusion imaging, but their role in patients with non-disabling symptoms appears very limited. Tenecteplase is superior to alteplase in meta-analysis of the latest trials, and adjuvant thrombolytics are an area of active investigation. Endovascular thrombectomy is beneficial in a wide range of anterior and posterior circulation large vessel occlusions up to 24 h after onset with the more distal occlusions, mild presentations, and >24 h window being the main frontiers to be tested in ongoing trials. Imaging parameters are prognostic but appear not to modify the relative treatment benefit of thrombectomy versus standard medical care. Therefore, deciding who not to treat with thrombectomy is a key clinical challenge that requires careful but rapid integration of clinical, imaging, and patient preference considerations. Systems of care to accelerate delivery of these highly effective therapies will maximize benefits for the greatest number of patients with stroke.

peripheral vascular disease,clinical neurology
For “time is the brain”, what can be done prehospital

Rui Liu,Wei Li,Huaiming Wang,Zhongmin Qiu,Wenjie Zi,Hao Zhang

DOI: https://doi.org/10.21037/amj.2017.06.01

2017-06-07

AME Medical Journal

Abstract:Acute ischemic stroke, which is one of the leading causes of death or permanent disability, can be treated with intravenous recombinant tissue plasminogen activator (tPA) within 4.5 h or intraarterial treatment (IAT) within 8 h. Time from symptom onset to initiation of treatment has a close relationship with the good outcome. But in actual clinical practice, it is difficult to ensure that acute ischemic stroke (AIS) patients can get treatment within the time window. To reduce the delay, many methods have been established for fast prehospital treatment, including stroke public awareness, treatment of emergency medical services, patient information transmission, and mobile stroke unit (MSU). Stroke educational campaigns are promoted to improve the patients and relatives’ awareness of the correct response to the stroke. When the stroke occurs, the role of emergency medical services (EMS) can be reflected. Telemedicine interaction between the two hospitals has a positive impact on thrombolysis rates and clinical outcomes. According to the MSU used, shorter time needed to treatment, and increased proportion of patients treated within the time window. In this review, we describe the importance of time for acute stroke therapy, analyze the possible causes of time delay, present the main methods of saving time in the clinic, and analyze the problems of these methods.

English Else
Live attenuated rubella virus vaccines prepared in duck embryo cell culture. II. Clinical tests in families and in an institution.

R. Weibel,J. Stokes,E. Buynak,J. Whitman,M. B. Leagus,M. Hilleman

DOI: https://doi.org/10.1001/JAMA.1968.03140340024005

1968-08-19

Abstract:Duck embryo cell culture rubella virus vaccines prepared with the HPV-77 (Meyer-Parkman) and the Merck (B-level attenuation) strains of virus were evaluated in a large-scale family study in the open community and in an institution. Of 265 initially seronegative children vaccinated with the HPV-77 virus in duck embryo cell culture, 97% responded serologically with a geometric mean hemagglutination-inhibiting (HI) titer of 1:53.2. There was no apparent clinical illness and no serologic evidence for contact spread to 262 susceptible siblings or to 34 maternal contacts. The performance of the Merck B-level vaccine in duck embryo cell culture in the smaller institutional study was essentially the same as that of the HPV-77 except that the mean HI titer was almost three times as great (1:148.3). Both vaccines proved safe and efficacious in children, and community studies are in progress in larger numbers of persons.
Progress of Therapeutic Time Window for Acute Ischemic Stroke

Wei LI,Xin-Feng LIU

DOI: https://doi.org/10.3969/j.issn.1673-5765.2018.04.012

2018-01-01

Abstract:Recanalization treatment for acute ischemic stroke is a complicated clinical intervention process, which involves multiple factors and points. Over a long period of time, the concept of "Time Window" is widely used in clinical practice. The efficacy and safety of thrombolytic therapy administered within 3 hours of symptom onset in the treatment of acute ischemic stroke had been proved in 1996. However, beyond the limit of the therapeutic time window and late to medical attention, the safety and validity of recanalization treatment for acute ischemic stroke cannot be ensured by the only "Time Window". Is there any individual difference in "Time window" based on the different baseline cerebral arterial lesion, collateral circulation and ability of ischemic stroke? With the development and progress of neuroimaging technology, scholars home and abroad have been working on how to extend the therapeutic time window over the past 20 years.
New mechanisms-based therapies in acute ischaemic stroke

Guido Stoll,Michael K Schuhmann,Alexander M Kollikowski,Mirko Pham

DOI: https://doi.org/10.1093/eurheartj/ehad865

IF: 39.3

2024-01-10

European Heart Journal

Abstract:Rapid reconstitution of blood flow by recanalization has been the primary therapeutic strategy in acute ischaemic stroke (AIS) after large vessel occlusion (LVO). In recent years, thrombolysis and endovascular mechanical thrombectomy (EVT), alone or combined, have seen ongoing refinement, including the extension of treatment time windows. Despite nearly achieving a 100% technical success rate in EVT for full recanalization (referred to as eTICI ≥ 2b), the individual prognosis of LVO stroke remains poor, with only about 35%–55% favourable outcome and 14%–28% mortality at 3 months. 1 Mortality reaches 36%–40% when infarcts have progressed to consume large brain volumes before EVT recanalization is performed. 2 These data show that recanalization is a pre-requisite for a better functional outcome, but individual prognosis remains poor for a large group of treated patients. This calls for add-on treatments. Experimental stroke models and observational clinical studies strongly indicate that progressive brain infarction throughout the delay from onset to treatment (during occlusion) and beyond successful recanalization [ischaemia/reperfusion (I/R) injury] mostly account for poor outcome. Novel mechanisms-based pharmacological approaches to delay or limit progressive brain infarction, such as classical neuroprotection 3 and targeting stroke-induced inflammation, 4 are currently in clinical development.

cardiac & cardiovascular systems
Neurovascular Inflammation and Complications of Thrombolysis Therapy in Stroke

Qiang Liu,Kaibin Shi,Yongjun Wang,Fu-Dong Shi

DOI: https://doi.org/10.1161/strokeaha.123.044123

IF: 10.17

2023-09-09

Stroke

Abstract:Stroke, Ahead of Print. Intravenous thrombolysis via tPA (tissue-type plasminogen activator) is the only approved pharmacological treatment for acute ischemic stroke, but its benefits are limited by hemorrhagic transformation. Emerging evidence reveals that tPA swiftly mobilizes immune cells which extravasate into the brain parenchyma via the cerebral vasculature, augmenting neurovascular inflammation, and tissue injury. In this review, we summarize the pronounced alterations of immune cells induced by tPA in patients with stroke and experimental stroke models. We argue that neuroinflammation, triggered by ischemia-induced cell death and exacerbated by tPA, compromises neurovascular integrity and the microcirculation, leading to hemorrhagic transformation. Finally, we discuss current and future approaches to attenuate thrombolysis-associated hemorrhagic transformation via uncoupling immune cells from the neurovascular unit.

peripheral vascular disease,clinical neurology
Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke

Hongyin Ma,Zhenmin Jiang,Jiayun Xu,Junqiu Liu,Zhen-Ni Guo

DOI: https://doi.org/10.1080/10717544.2021.1879315

IF: 6.819

2021-01-01

Drug Delivery

Abstract:<span>Ischemic stroke is one of the major causes of severe disability and death worldwide. It is mainly caused by a sudden reduction in cerebral blood flow due to obstruction of the supplying vessel by thrombi and subsequent initiation of a complex cascade of pathophysiological changes, which ultimately lead to brain ischemia and even irreversible infarction. Thus, timely and effective thrombolysis therapy remains a mainstay for acute ischemic stroke treatment. Tissue plasminogen activator (tPA), the only thrombolytic agent approved globally, provides substantial benefits by exerting a fibrinolysis effect, recovering the blood supply in occluded vessels and, thereby, salvaging the ischemic tissue. However, the clinical application of tPA was limited because of a few unsolved issues, such as a narrow therapeutic window, hemorrhagic complications, and limited thrombolytic efficacy, especially, for large thrombi. With the prosperous development of nanotechnology, a series of targeted delivery strategies and nanocomposites have been extensively investigated for delivering thrombolytic agents to facilitate thrombolysis treatment. Excitingly, numerous novel attempts have been reported to be effective in extending the half-life, targeting the thrombus site, and improving the thrombolytic efficacy in preclinical models. This article begins with a brief introduction to ischemic stroke, then describes the current state of thrombolysis treatment and, finally, introduces the application of various nanotechnology-based strategies for targeted delivery of thrombolytic agents. Representative studies are reviewed according to diverse strategies and nano-formulations, with the aim of providing integrated and up-to-date information and to improve the development of thrombolysis treatment for stroke patients.</span>

pharmacology & pharmacy

Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies

Endovascular Therapy in Acute Ischemic Stroke: Time is Brain

tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?

Silver Jubilee of Stroke Thrombolysis With Alteplase: Evolution of the Therapeutic Window

Drinking in a patchy environment: the effect of the price of water.

Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders

Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.

Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries

Thrombolysis in Neuromedicine

What is the Role for Intra-Arterial Therapy in Acute Stroke Intervention?

Intra-arterial neuroprotective therapy as an adjunct to endovascular intervention in acute ischemic stroke: A review of the literature and future directions

Current and future perspectives on the treatment of cerebral ischemia

Emerging agents for the treatment and prevention of stroke: progress in clinical trials

A pilot protocol and review of triple neuroprotection with targeted hypothermia, controlled induced hypertension, and barbiturate infusion during emergency carotid endarterectomy for acute stroke after failed tPA or beyond 24-hour window of opportunity

Hyperacute ischemic stroke care—Current treatment and future directions

For “time is the brain”, what can be done prehospital

Live attenuated rubella virus vaccines prepared in duck embryo cell culture. II. Clinical tests in families and in an institution.

Progress of Therapeutic Time Window for Acute Ischemic Stroke

New mechanisms-based therapies in acute ischaemic stroke

Neurovascular Inflammation and Complications of Thrombolysis Therapy in Stroke

Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke